Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a commercial-stage medical technology company that focuses on the development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems. These systems measure glucose levels through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients in the United States and globally.

Senseonics Holdings, Inc. is listed on the NasdaqGS exchange under the ticker symbol SENS. The company operates in the United States and its stock is traded in US Dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and trading are conducted in USD, making it accessible to investors in the US and international markets.

Senseonics Holdings, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical technology company, it develops and manufactures implantable continuous glucose monitoring systems for diabetes management. The Medical Devices industry encompasses a wide range of products used in diagnosis, monitoring, and treatment of medical conditions, and Senseonics focuses on the diabetes care segment with its innovative CGM technology.

Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, United States. The company was founded in 1996 and serves healthcare providers and patients in the United States and globally. Its products are distributed through a network of distributors and strategic fulfillment partners, allowing it to reach customers in multiple countries. The company's global presence enables it to address the needs of people with diabetes worldwide.

Senseonics' main products are the Eversense, Eversense XL, Eversense E3, and Eversense 365 continuous glucose monitoring (CGM) systems. These are implantable CGM systems that measure glucose levels in people with diabetes. The system consists of an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile app for real-time diabetes monitoring and management. The sensor is inserted subcutaneously and can be worn for extended periods, providing continuous glucose data to help users manage their condition effectively.